

## Texas Standard Prior Authorization Form Addendum

## **Molina Healthcare of Texas**

## **Anxiolytics – Clonazepam & Diazepam (Medicaid)**

This fax machine is located in a secure location as required by HIPAA Regulations. Complete / Review information, sign, and date. Fax signed forms to Molina Pharmacy Prior Authorization Department at **1-888-487-9251**. Please contact Molina Pharmacy Prior Authorization Department at **1-855-322-4080** with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Anxiolytics – Clonazepam & Diazepam (Medicaid).

	Drug Name (sel	ect from list of drugs show	n / provide drug information)		
CLONAZEPAM DIS TAB		CLONAZEPAM (	ODT CLONAZ	ZEPAM	
DIAZEPA	M	KLONOPIN			
		Patient Informat	ion		
Patient Name:					
Patient ID:					
Patient DOB:					
		Prescribing Physi	cian		
Physician Name:					
Physician Phone:					
Physician Fax:					
Physician Address:					
City, State, Zip:					
Diagnosis:		ICD (	Code:		
Directions for administ	ration:				
Please circle the approp	oriate answer for	each question. urt order? (court order requi	n history and any other applicabl	e documentatio	on. N
If the answer to this quantity.  2. Does the patient hat If the answer to this quantity.	question is no, go to ve a history of a question is yes, go t	o question 2.  Clonazepam or diazepam age o question 3.	ent for 90 days in the last 150 days?	Y	N
3. Is this request for a If the answer to this of If the If If the If the If the If the If If the If the If If the If If the If	non-preferred dr	ug? o question 4.		Y	N
4. Has the patient faile  If the answer to this a  If the answer to this a	question is yes, app	roved for 365 days.	erred agent within the last 180 days	s? Y	N

5.	Is there a documented allergy or contraindication to preferred agents in this class? If the answer to this question is yes, approved for 365 days. If the answer to this question is no, go to question 6.		Y	N
6.	Is the drug necessary for treatment of stage-4 advanced metastatic cancer and associated conditions? If the answer to this question is yes, approved for 365 days. If the answer to this question is no, denied.		Y	N
7.	Is the incoming request for less than or equal to 1 days supply? If the answer to this question is yes, go to question 8. If the answer to this question is no, go to question 13.		Y	N
8.	Is the incoming request for less than or equal to 5 units per day? If the answer to this question is yes, go to question 9. If the answer to this question is no, go to question 13.		Y	N
9.	Is this request for a non-preferred drug?  If the answer to this question is yes, go to question 10.  If the answer to this question is no, approved for 1 day.		Y	N
10.	Has the patient failed a 30 day treatment trial with at least 1 preferred agent within the last 180 days? If the answer to this question is yes, approved for 1 day. If the answer to this question is no, go to question 11.		Y	N
11.	Is there a documented allergy or contraindication to preferred agents in this class? If the answer to this question is yes, approved for 1 day. If the answer to this question is no, go to question 12.	Y	N	
12.	Is the drug necessary for treatment of stage-4 advanced metastatic cancer and associated conditions? If the answer to this question is yes, approved for 1 day.  If the answer to this question is no, denied.		Y	N
13.	Does the patient have a diagnosis of epilepsy in the last 730 days? If the answer to this question is yes, go to question 14. If the answer to this question is no, go to question 18.		Y	N
14.	Is this request for a non-preferred drug?  If the answer to this question is yes, go to question 15.  If the answer to this question is no, approved for 365 days.		Y	N
15.	Has the patient failed a 30 day treatment trial with at least 1 preferred agent within the last 180 days? If the answer to this question is yes, approved for 365 days. If the answer to this question is no, go to question 16.		Y	N
16.	Is there a documented allergy or contraindication to preferred agents in this class? If the answer to this question is yes, approved for 365 days. If the answer to this question is no, go to question 17.		Y	N
17.	Is the drug necessary for treatment of stage-4 advanced metastatic cancer and associated conditions? If the answer to this question is yes, approved for 365 days. If the answer to this question is no, denied.		Y	N
18.	Does the patient have a history of an anticonvulsant agent in the last 45 days? If the answer to this question is yes, go to question 19. If the answer to this question is no, go to question 23.		Y	N
19.	Is this request for a non-preferred drug?  If the answer to this question is yes, go to question 20.  If the answer to this question is no, approved for 365 days.		Y	N

20.	Has the patient failed a 30-day treatment trial with at least 1 preferred agent within the last 180 days? If the answer to this question is yes, approved for 365 days. If the answer to this question is no, go to question 21.	Y	N
21.	Is there a documented allergy or contraindication to preferred agents in this class? If the answer to this question is yes, approved for 365 days. If the answer to this question is no, go to question 22.	Y	N
22.	Is the drug necessary for treatment of stage-4 advanced metastatic cancer and associated conditions? If the answer to this question is yes, approved for 365 days.  If the answer to this question is no, denied.	Y	N
23.	Does the patient have a diagnosis of a muscle disorder in the last 730 days? If the answer to this question is yes, go to question 24. If the answer to this question is no, go to question 28.	Y	N
24.	Is this request for a non-preferred drug?  If the answer to this question is yes, go to question 25.  If the answer to this question is no, approved for 365 days.	Y	N
25.	Has the patient failed a 30-day treatment trial with at least 1 preferred agent within the last 180 days? If the answer to this question is yes, approved for 365 days. If the answer to this question is no, go to question 26.	Y	N
26.	Is there documented allergy or contraindication to preferred agents in this class? If the answer to this question is yes, approved for 365 days. If the answer to this question is no, go to question 27.	Y	N
27.	Is the drug necessary for treatment of stage-4 advanced metastatic cancer and associated conditions? If the answer to this question is yes, approved for 365 days. If the answer to this question is no, denied.	Y	N
28.	Does the patient have a diagnosis of an anxiety disorder in the last 730 days? If the answer to this question is yes, go to question 30. If the answer to this question is no, go to question 29.	Y	N
29.	Does the patient have a diagnosis of drug abuse in the last 730 days? If the answer to this question is yes, denied. If the answer to this question is no, go to question 30.	Y	N
30.	Is the patient less than 6 months of age?  If the answer to this question is yes, denied  If the answer to this question is no, go to question 31.	Y	N
31.	Is the patient between 6 months to 18 years of age?  If the answer to this question is yes, go to question 32.  If the answer to this question is no, go to question 43.	Y	N
32.	Does the patient have a diagnosis of anxiety disorder in the last 730 days? If the answer to this question is yes, go to question 33.  If the answer to this question is no, go to question 38.	Y	N
33.	Does the patient have a history of an anxiolytic agent for 60 days in the last 90 days? If the answer to this question is yes, denied If the answer to this question is no, go to question 34.	Y	N
34.	Is this request for a non-preferred drug?  If the answer to this question is yes, go to question 35.  If the answer to this question is no, approved for 60 days.	Y	N

35.	Has the patient failed a 30-day treatment trial with at least 1 preferred agent within the last 180 days? If the answer to this question is yes, approved for 60 days. If the answer to this question is no, go to question 36.	Y	N
36.	Is there a documented allergy or contraindication to preferred agents in this class? If the answer to this question is yes, approved for 60 days. If the answer to this question is no, go to question 37.	Y	N
37.	Is the drug necessary for treatment of stage-4 advanced metastatic cancer and associated conditions? If the answer to this question is yes, approved for 60 days.  If the answer to this question is no, denied.	Y	N
38.	Does the patient have a history of an anxiolytic agent for 30 days in the last 60 days? If the answer to this question is yes, denied. If the answer to this question is no, go to question 39.	Y	N
39.	Is this request for a non-preferred drug?  If the answer to this question is yes, go to question 40.  If the answer to this question is no, approved for 30 days.	Y	N
40.	Has the patient failed a 30-day treatment trial with at least 1 preferred agent within the last 180 days? If the answer to this question is yes, approved for 30 days. If the answer to this question is no, go to question 41.	Y	N
41.	Is there documented allergy or contraindication to preferred agents in this class? If the answer to this question is yes, approved for 30 days. If the answer to this question is no, go to question 42.	Y	N
42.	Is the drug necessary for treatment of stage-4 advanced metastatic cancer and associated conditions? If the answer to this question is yes, approved for 30 days.  If the answer to this question is no, denied.	Y	N
43.	Does the patient have a diagnosis of anxiety disorder in the last 730 days? If the answer to this question is yes, go to question 44. If the answer to this question is no, go to question 49.	Y	N
44.	Does the patient have a history of an anxiolytic agent for 180 days in the last 200 days? If the answer to this question is yes, denied.  If the answer to this question is no, go to question 45.	Y	N
45.	Is this request for a non-preferred drug?  If the answer to this question is yes, go to question 46.  If the answer to this question is no, approved for 180 days.	Y	N
46.	Has the patient failed a 30-day treatment trial with at least 1 preferred agent within the last 180 days? If the answer to this question is yes, approved for 180 days. If the answer to this question is no, go to question 47.	Y	N
47.	Is there a documented allergy or contraindication to preferred agents in this class? If the answer to this question is yes, approved for 180 days. If the answer to this question is no, go to question 48.	Y	N
48.	Is the drug necessary for treatment of stage-4 advanced metastatic cancer and associated conditions? If the answer to this question is yes, approved for 180 days. If the answer to this question is no, denied.	Y	N
	Does the patient have a history of an anxiolytic agent for 60 days in the last 90 days? If the answer to this question is yes, denied.  If the answer to this question is no, go to question 50.  PAI21115-95. 04302021-C14587-A	Y	N

— Pre	escriber (or Authorized) Signature Date		
Ιą	ffirm that the information given on this form is true and accurate as of this date.		
Co	mments:		
53.	Is the drug necessary for treatment of stage-4 advanced metastatic cancer and associated conditions? If the answer to this question is yes, approved for 60 days. If the answer to this question is no, denied.	Y	N
52.	Is there a documented allergy or contraindication to preferred agents in this class? If the answer to this question is yes, approved for 60 days. If the answer to this question is no, go to question 53.	Y	N
51.	Has the patient failed a 30-day treatment trial with at least 1 preferred agent within the last 180 days? If the answer to this question is yes, approved for 60 days. If the answer to this question is no, go to question 52.	Y	N
30.	If the answer to this question is yes, go to question 51.  If the answer to this question is no, approved for 60 days.	ĭ	Γ